P
PAQ Therapeutics
Pioneering a new approach to restoring health and curing disease through autophagy
About PAQ Therapeutics
PAQ Therapeutics is a pioneering biotechnology startup focused on developing innovative treatments for neurodegenerative diseases. Founded by Dr. Boxun Lu, a globally recognized expert in life sciences and a professor at Fudan University, the company leverages cutting-edge research to address conditions like Huntington's disease, familial ALS, and other polyQ diseases. Dr. Lu's groundbreaking work on ATTEC (Autophagy-Tethering Compounds) forms the scientific backbone of PAQ Therapeutics. This technology aims to harness the body's natural process of autophagy, which is the way cells clean out damaged components, to target and eliminate toxic proteins that cause neurodegenerative diseases.
PAQ Therapeutics operates primarily in the biopharmaceutical market, targeting both academic research institutions and pharmaceutical companies. Their clients include researchers looking for advanced tools to study neurodegeneration and pharmaceutical firms seeking new therapeutic avenues. The company’s business model revolves around the development and licensing of its proprietary ATTEC technology. By partnering with larger pharmaceutical companies, PAQ Therapeutics can co-develop drugs and share in the profits from successful treatments. Additionally, they may receive milestone payments and royalties as their partnered drugs progress through clinical trials and into the market.
Revenue generation for PAQ Therapeutics comes from multiple streams: licensing fees, research grants, and collaborative agreements with pharmaceutical companies. These partnerships not only provide financial support but also accelerate the development and commercialization of their innovative therapies.
In summary, PAQ Therapeutics is at the forefront of biopharmaceutical innovation, focusing on the development of novel treatments for neurodegenerative diseases through its proprietary ATTEC technology. The company serves academic and pharmaceutical clients, operates within the biopharmaceutical market, and generates revenue through licensing, grants, and partnerships.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2026 | $38M | $195M | Undisclosed | ↗ |
| SERIES BOther financing | May 2025 | $39M | $156M | Johnson & Johnson Innovation · Sherpa Venture Partners · MRL Ventures · BioTrack Capital | ↗ |
Growth signals
Latest recorded traffic for PAQ Therapeutics is 320 monthly website visits, down 17.9% over the last three months. PAQ Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
PAQ Therapeutics in the Burlington ecosystem
The PAQ Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Nest.Bio Labs
Matrix Partners China
Series A7 investors entered at this stage
Sherpa Venture Partners
MSA Capital
Huagai Capital
MRL Ventures
Johnson & Johnson Innovation
BioTrack Capital- LALAV
Other known investors1 additional known investor
Fudan University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about PAQ Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See PAQ Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









